HIAT2015 - List of Authors (Laxdal, R.E.)

Paper

Title

Page

FRIB Accelerator: Design and Construction Status

6

J. Wei, H. Ao, N.K. Bultman, F. Casagrande, C. Compton, L.R. Dalesio, K.D. Davidson, B. Durickovic, A. Facco, F. Feyzi, A. Ganshin, P.E. Gibson, T. Glasmacher, W. Hartung, L. Hodges, L.T. Hoff, K. Holland, H.-C. Hseuh, A. Hussain, M. Ikegami, S. Jones, K. Kranz, R.E. Laxdal, S.M. Lidia, S.M. Lund, G. Machicoane, F. Marti, S.J. Miller, D. Morris, J.A. Nolen, S. Peng, J. Popielarski, L. Popielarski, G. Pozdeyev, T. Russo, K. Saito, G. Shen, S. Stanley, T. Xu, Y. Yamazaki
FRIB, East Lansing, Michigan, USA
K. Dixon, V. Ganni, M. Wiseman
JLab, Newport News, Virginia, USA
A. Facco
INFN/LNL, Legnaro (PD), Italy
H.-C. Hseuh
BNL, Upton, Long Island, New York, USA
M.P. Kelly, J.A. Nolen, P.N. Ostroumov
ANL, Argonne, USA
R.E. Laxdal
TRIUMF, Canada's National Laboratory for Particle and Nuclear Physics, Vancouver, Canada

Funding: Work supported by the U.S. Department of Energy Office of Science under Cooperative Agreement DE-SC0000661.
The Facility for Rare Isotope Beams (FRIB) is based on a continuous-wave superconducting heavy ion linac to accelerate all the stable isotopes to above 200 MeV/u with a beam power of up to 400 kW. At an average beam power approximately two-to-three orders-of-magnitude higher than those of operating heavy-ion facilities, FRIB stands at the power frontier of the accelerator family - the first time for heavy-ion accelerators. In August 2014, the FRIB Project entered into full construction phase. Based on verified innovative designs, the FRIB accelerator team is working closely with partner laboratories and contracted industrial providers on the construction, installation and commissioning of the facility. This report summarizes the current design and construction status.

Slides MOM1I02 [39.840 MB]

Export •

reference for this paper to ※ BibTeX, ※ LaTeX, ※ Text, ※ RIS/RefMan, ※ EndNote (xml)

MOM2I02

Isotopes for Science and Medicine: The Pursuit, Study and Application of Medical Isotopes at TRIUMF

P. Schaffer, J. Crawford, P. Kunz, R.E. Laxdal, C. Ramogida, T..J. Ruth
TRIUMF, Canada's National Laboratory for Particle and Nuclear Physics, Vancouver, Canada

Medical isotope research at TRIUMF is enabled by a fleet of proton accelerators, ranging from 13 to 500 MeV, coupled to deep expertise in high-power accelerator target design, isotope production and radiopharmaceutical chemistry. With these tools and knowledge, scientists at TRIUMF are pursuing applications in molecular imaging and targeted radiotherapy using known and novel isotopes. A brief update on recent efforts to demonstrate accelerator-based production of 99mTc via 100Mo(p, 2n) will be provided, followed by a summary of work on isotopes with potential theranostic applications. Recent efforts in the production and isolation of 209, 211At, 223, 224,225Ra, 225Ac and 213Bi from proton irradiation of 232Th will be discussed. Using TRIUMF's ISOL infrastructure, 209At, a γ-emitter, was isolated via implantation of 213Fr and used to label and image model targeting vectors in vivo. In parallel, 211At (via 211Rn implantation) was isolated as a promising α-emitting isotope to treat micro-metastases or monocellular malignancies such as leukemia. The implantation of 223, 224Ra as well as 225Ra, a parent of 225Ac and concomitantly 213Bi, were also studied as a means to obtain these promising isotopes with similar applications in targeted α-therapy. This presentation will conclude with a summary of TRIUMF's activities toward completing its 50 MeV, 500 kW Advanced Rare Isotope Laboratory (ARIEL), a high-intensity e-linac.

Slides MOM2I02 [8.351 MB]

Export •

reference for this paper to ※ BibTeX, ※ LaTeX, ※ Text, ※ RIS/RefMan, ※ EndNote (xml)

WEM2I01

The ISAC-II Linac Performance

175

M. Marchetto, S. Kiy, R.E. Laxdal, Y. Ma, O. Shelbaya, Z.Y. Yao, V. Zvyagintsev
TRIUMF, Canada's National Laboratory for Particle and Nuclear Physics, Vancouver, Canada

Funding: Funded under a contribution agreement with NRC (National Research Council Canada)
The ISAC-II superconducting linac is operating for almost a decade. The first installation includes twenty cavities housed in five cryomodules. The Phase II upgrade consisted of twenty additional cavities housed in three cryomodules. The upgrade brings the linac to a nominal 40 MV of effective accelerating voltage according to design specification. Moreover the upgrade was the first step to qualify a Canadian vendor (PAVAC) for the production of superconducting cavities. Each cryomodule includes bulk niobium quarter wave resonators and a 9T superconducting solenoid for transverse focusing. The linac features a single vacuum space. Over the years the linac has experienced vacuum incidents and high power rf cable failures in vacuum that were addressed during maintenance. In a recent maintenance program cavities from a single cryomodule were re-etched to improve performance. Future cavity treatments are in the plan but they are restricted by the scientific program. The status of the linac, performance and future development plans will be presented. Reliability and availability of the linac will be discussed, metrics that will become even more important with the advent of ARIEL.

Slides WEM2I01 [14.869 MB]

Export •

reference for this paper to ※ BibTeX, ※ LaTeX, ※ Text, ※ RIS/RefMan, ※ EndNote (xml)

Paper	Title	Page
MOM1I02	FRIB Accelerator: Design and Construction Status	6
	J. Wei, H. Ao, N.K. Bultman, F. Casagrande, C. Compton, L.R. Dalesio, K.D. Davidson, B. Durickovic, A. Facco, F. Feyzi, A. Ganshin, P.E. Gibson, T. Glasmacher, W. Hartung, L. Hodges, L.T. Hoff, K. Holland, H.-C. Hseuh, A. Hussain, M. Ikegami, S. Jones, K. Kranz, R.E. Laxdal, S.M. Lidia, S.M. Lund, G. Machicoane, F. Marti, S.J. Miller, D. Morris, J.A. Nolen, S. Peng, J. Popielarski, L. Popielarski, G. Pozdeyev, T. Russo, K. Saito, G. Shen, S. Stanley, T. Xu, Y. Yamazaki FRIB, East Lansing, Michigan, USA K. Dixon, V. Ganni, M. Wiseman JLab, Newport News, Virginia, USA A. Facco INFN/LNL, Legnaro (PD), Italy H.-C. Hseuh BNL, Upton, Long Island, New York, USA M.P. Kelly, J.A. Nolen, P.N. Ostroumov ANL, Argonne, USA R.E. Laxdal TRIUMF, Canada's National Laboratory for Particle and Nuclear Physics, Vancouver, Canada
	Funding: Work supported by the U.S. Department of Energy Office of Science under Cooperative Agreement DE-SC0000661. The Facility for Rare Isotope Beams (FRIB) is based on a continuous-wave superconducting heavy ion linac to accelerate all the stable isotopes to above 200 MeV/u with a beam power of up to 400 kW. At an average beam power approximately two-to-three orders-of-magnitude higher than those of operating heavy-ion facilities, FRIB stands at the power frontier of the accelerator family - the first time for heavy-ion accelerators. In August 2014, the FRIB Project entered into full construction phase. Based on verified innovative designs, the FRIB accelerator team is working closely with partner laboratories and contracted industrial providers on the construction, installation and commissioning of the facility. This report summarizes the current design and construction status.
	Slides MOM1I02 [39.840 MB]
Export •	reference for this paper to ※ BibTeX, ※ LaTeX, ※ Text, ※ RIS/RefMan, ※ EndNote (xml)

MOM2I02	Isotopes for Science and Medicine: The Pursuit, Study and Application of Medical Isotopes at TRIUMF
	P. Schaffer, J. Crawford, P. Kunz, R.E. Laxdal, C. Ramogida, T..J. Ruth TRIUMF, Canada's National Laboratory for Particle and Nuclear Physics, Vancouver, Canada
	Medical isotope research at TRIUMF is enabled by a fleet of proton accelerators, ranging from 13 to 500 MeV, coupled to deep expertise in high-power accelerator target design, isotope production and radiopharmaceutical chemistry. With these tools and knowledge, scientists at TRIUMF are pursuing applications in molecular imaging and targeted radiotherapy using known and novel isotopes. A brief update on recent efforts to demonstrate accelerator-based production of 99mTc via 100Mo(p, 2n) will be provided, followed by a summary of work on isotopes with potential theranostic applications. Recent efforts in the production and isolation of 209, 211At, 223, 224,225Ra, 225Ac and 213Bi from proton irradiation of 232Th will be discussed. Using TRIUMF's ISOL infrastructure, 209At, a γ-emitter, was isolated via implantation of 213Fr and used to label and image model targeting vectors in vivo. In parallel, 211At (via 211Rn implantation) was isolated as a promising α-emitting isotope to treat micro-metastases or monocellular malignancies such as leukemia. The implantation of 223, 224Ra as well as 225Ra, a parent of 225Ac and concomitantly 213Bi, were also studied as a means to obtain these promising isotopes with similar applications in targeted α-therapy. This presentation will conclude with a summary of TRIUMF's activities toward completing its 50 MeV, 500 kW Advanced Rare Isotope Laboratory (ARIEL), a high-intensity e-linac.
	Slides MOM2I02 [8.351 MB]
Export •	reference for this paper to ※ BibTeX, ※ LaTeX, ※ Text, ※ RIS/RefMan, ※ EndNote (xml)

WEM2I01	The ISAC-II Linac Performance	175
	M. Marchetto, S. Kiy, R.E. Laxdal, Y. Ma, O. Shelbaya, Z.Y. Yao, V. Zvyagintsev TRIUMF, Canada's National Laboratory for Particle and Nuclear Physics, Vancouver, Canada
	Funding: Funded under a contribution agreement with NRC (National Research Council Canada) The ISAC-II superconducting linac is operating for almost a decade. The first installation includes twenty cavities housed in five cryomodules. The Phase II upgrade consisted of twenty additional cavities housed in three cryomodules. The upgrade brings the linac to a nominal 40 MV of effective accelerating voltage according to design specification. Moreover the upgrade was the first step to qualify a Canadian vendor (PAVAC) for the production of superconducting cavities. Each cryomodule includes bulk niobium quarter wave resonators and a 9T superconducting solenoid for transverse focusing. The linac features a single vacuum space. Over the years the linac has experienced vacuum incidents and high power rf cable failures in vacuum that were addressed during maintenance. In a recent maintenance program cavities from a single cryomodule were re-etched to improve performance. Future cavity treatments are in the plan but they are restricted by the scientific program. The status of the linac, performance and future development plans will be presented. Reliability and availability of the linac will be discussed, metrics that will become even more important with the advent of ARIEL.
	Slides WEM2I01 [14.869 MB]
Export •	reference for this paper to ※ BibTeX, ※ LaTeX, ※ Text, ※ RIS/RefMan, ※ EndNote (xml)